MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Viking Therapeutics Inc

Deschisă

SectorSănătate

24.52 -4.78

Rezumat

Modificarea prețului

24h

Curent

Minim

24.3

Maxim

25.87

Indicatori cheie

By Trading Economics

Venit

-10M

-35M

EPS

-0.32

Angajați

36

EBITDA

-9.6M

-46M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+248.66% upside

Dividende

By Dow Jones

Următoarele câștiguri

23 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-570M

2.7B

Deschiderea anterioară

29.3

Închiderea anterioară

24.52

Scor tehnic

By Trading Central

Încredere

Very Strong Bullish Evidence

Viking Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

14 apr. 2025, 14:14 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Viking Seen as Potential Ticket To Get Pfizer Back Into Obesity Game -- Market Talk

7 feb. 2025, 10:30 UTC

Top știri

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

23 dec. 2024, 15:04 UTC

Top știri

Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark. -- Barrons.com

13 dec. 2024, 14:53 UTC

Top știri

Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling. -- Barrons.com

4 nov. 2024, 12:22 UTC

Top știri

Viking Therapeutics Jumps On Latest Obesity Drug Data -- IBD

4 nov. 2024, 12:00 UTC

Top știri

Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ

4 nov. 2024, 10:11 UTC

Acțiuni populare

Stock to Watch Monday: Trump Media, Viking Therapeutics, Nvidia, Intel -- WSJ

4 oct. 2024, 12:01 UTC

Top știri

As Weight-Loss Drugs Battle, Upstart Viking -2-

4 oct. 2024, 12:01 UTC

Top știri

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer -- IBD

20 sept. 2024, 13:55 UTC

Top știri

Update: Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

25 iul. 2024, 15:03 UTC

Câștiguri

Viking Stock Jumps After Company Speeds Development Its Weight-Loss Pill -- Barrons.com

Comparație

Modificare preț

Viking Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

248.66% sus

Prognoză pe 12 luni

Medie 89.92 USD  248.66%

Maxim 125 USD

Minim 30 USD

În baza a 17 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruViking Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

17 ratings

15

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

25.48 / 25.7Suport & Rezistență

Termen scurt

Very Strong Bullish Evidence

Termen mediu

Weak Bearish Evidence

Termen lung

Weak Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.